Automate Your Wheel Strategy on CYTK
With Tiblio's Option Bot, you can configure your own wheel strategy including CYTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYTK
- Rev/Share 0.7177
- Book/Share -3.0866
- PB -19.646
- Debt/Equity -2.3271
- CurrentRatio 6.7642
- ROIC -0.4847
- MktCap 7256009940.0
- FreeCF/Share -3.6873
- PFCF -16.4731
- PE -11.9475
- Debt/Assets 0.7001
- DivYield 0
- ROE 3.0918
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CYTK | Raymond James | -- | Market Perform | -- | -- | July 30, 2025 |
| Initiation | CYTK | Barclays | -- | Overweight | -- | $55 | April 24, 2025 |
| Initiation | CYTK | Citigroup | -- | Buy | -- | $86 | Feb. 7, 2025 |
| Initiation | CYTK | Stifel | -- | Buy | -- | $80 | Jan. 22, 2025 |
News
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Oct. 3, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 01, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
Class Action Filed Against Cytokinetics, Incorporated (CYTK) - November 17, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
Read More
CYTOKINETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period").
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK
Published: September 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 24, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALL.
Read More
CYTK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In CYTK To Contact Him Directly To Discuss Their Options
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
Deadline Approaching: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Published: September 23, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK).
Read More
Class Action Filed Against Cytokinetics, Incorporated (CYTK) Seeking Recovery for Investors – Contact Levi & Korsinsky
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
Law Offices of Frank R. Cruz Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
Published: September 22, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) and certain of its officers.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Cytokinetics (CYTK) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process.
Read More
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $550.0 million.
Read More
Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytokinetics, Incorporated (NASDAQ:CYTK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Fady Malik - Executive Vice President of Research & Development Andrew Callos - Executive VP & Chief Commercial Officer Sung Lee - EVP & CFO Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst All right. Great. I'm Max Skor, a biotech analyst with Morgan Stanley.
Read More
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Read More
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Positive
MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies in aficamten's shorter half-life, faster titration, and cleaner safety profile, which may drive higher physician preference despite BMS's head start.
Read More
Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universatario Carolyn Ho - Medical Director of the Cardiovascular Genetic Center Ahmad Masri - Cardiomyopathy Section Head and Director, Hypertrophic Cardiomyopathy Center Anjali Owens - Medical Director, Inherited Cardiac Disease Presentation Diane Weiser Senior Vice President of Corporate Affairs Welcome, everyone, and thanks for joining.
Read More
Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.
Published: September 02, 2025 by: Barrons
Sentiment: Positive
Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.
Read More
Cytokinetics Merits A Speculative Buy Rating
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug candidate was delayed by three months recently. However, Cytokinetics maintains a robust cash position of $1.1 billion, supporting ongoing operations and R&D. If all goes according to schedule, Cytokinetics should receive the first of many FDA approvals late this year and has several potential catalysts on the horizon.
Read More
About Cytokinetics, Incorporated (CYTK)
- IPO Date 2004-04-30
- Website https://www.cytokinetics.com
- Industry Biotechnology
- CEO Robert I. Blum
- Employees 498